Vascular transplantation with dual-biofunctional ePTFE vascular grafts in a porcine model,Journal of Materials Chemistry B

当前位置： X-MOL 学术 › J. Mater. Chem. B › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

Vascular transplantation with dual-biofunctional ePTFE vascular grafts in a porcine model
Journal of Materials Chemistry B ( IF 6.1 ) Pub Date : 2021-08-02 , DOI: 10.1039/d1tb01398j
Zheng Xing ₁ , Shuting Wu ₂ , Chen Zhao ₃ , Yating Bai ₁ , Dawei Jin ₂ , Meng Yin ₂ , Haifeng Liu ₁ , Yubo Fan ₁

Affiliation

Cardiovascular disease (CVD) poses serious health concerns worldwide. The lack of transplantable vascular grafts is an unmet clinical need in the surgical treatment of CVD. Although expanded polytetrafluoroethylene (ePTFE) vascular grafts have been used in clinical practice, a low long-term patency rate in small-diameter transplantation application is still the biggest challenge. Thus, surface modification of ePTFE is sought after. In this study, polydopamine (PDA) was used to improve the hydrophilia and provide immobilization sites in ePTFE. Bivalirudin (BVLD), a direct thrombin inhibitor, was used to enhance the anti-thrombotic activity of ePTFE. The peptides derived from extracellular matrix proteins were used to elevate the bioactivity of ePTFE. The morphology, chemical composition, peptide modified strength, wettability, and hemocompatibility of modified ePTFE vascular grafts were investigated. Then, an endothelial cell proliferation assay was used to evaluate the best co-modification strategy of the ePTFE vascular graft in vitro. Since a large animal could relatively better mimic human physiology, we chose a porcine carotid artery replacement model in the current study. The results showed that the BVLD/REDV co-modified ePTFE vascular grafts had a satisfactory patency rate (66.7%) and a higher endothelial cell coverage ratio (70%) at 12 weeks after implantation. This may offer an opportunity to produce a multi-biofunctional ePTFE vascular graft, thereby yielding a potent product to meet the clinical needs.

中文翻译：

在猪模型中使用双生物功能 ePTFE 血管移植物进行血管移植

心血管疾病 (CVD) 在全球范围内引起严重的健康问题。缺乏可移植的血管移植物是 CVD 手术治疗中未满足的临床需求。尽管膨体聚四氟乙烯（ePTFE）血管移植物已应用于临床，但小直径移植应用中长期通畅率低仍然是最大的挑战。因此，寻求ePTFE的表面改性。在这项研究中，聚多巴胺 (PDA) 用于改善亲水性并在 ePTFE 中提供固定位点。比伐卢定 (BVLD) 是一种直接凝血酶抑制剂，用于增强 ePTFE 的抗血栓形成活性。来源于细胞外基质蛋白的肽用于提高 ePTFE 的生物活性。形态、化学成分、肽修饰强度、润湿性、研究了改性 ePTFE 血管移植物的血液相容性和血液相容性。然后，使用内皮细胞增殖试验评估 ePTFE 血管移植物的最佳共修饰策略体外。由于大型动物可以相对更好地模拟人类生理，我们在当前研究中选择了猪颈动脉置换模型。结果表明，BVLD/REDV共修饰的ePTFE血管移植物在植入后12周具有令人满意的通畅率（66.7%）和较高的内皮细胞覆盖率（70%）。这可能为生产多功能 ePTFE 血管移植物提供机会，从而生产出满足临床需求的有效产品。

更新日期：2021-08-27

点击分享查看原文

点击收藏

阅读更多本刊最新论文本刊介绍/投稿指南11